Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Postoperative brain tumor MRI comparing TGSE-BLADE and RESOLVE DWI showing distortion reduction near resection site

Improving Postoperative Brain Tumor MRI: TGSE-BLADE vs. RESOLVE DWI

Early MRI scans are critical for patients who have just undergone brain tumor resection to evaluate the surgery's success and plan future treatments.…

CRA requesting a radiology read using mint Lesion Clinical Trial Request Portal

Centralized Management for Clinical Trial Communications and Workflows

Requests for radiological clinical trial evaluations frequently rely on fragmented methods such as emails, phone calls, and spreadsheets. This…

Participants at the RECIST and Beyond workshop in Cologne during hands-on training with mint Lesion for structured tumor response assessment.

Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging

How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?